Bird & Bird advises Vanagon Ventures on pre-seed investment in ExoMatter

Contacts

andrea schlote Module
Andrea Schlote

Counsel
Germany

As a Counsel in our Corporate / M&A Team in Munich, I focus on domestic and international venture capital and venture lending transactions for emerging and high-growth companies.

International law firm Bird & Bird has advised Vanagon Ventures as lead investor in the pre-seed financing round of ExoMatter.

ExoMatter is revolutionising the field of materials research by using  AI and quantum mechanical modelling. The company also shortens the materials development process by up to 90%, reducing the associated costs and greenhouse gas emissions. The pre-seed financing will enable the AI startup to continue its growth strategy.

Vanagon Ventures is a Climate DeepTech venture capital fund founded in 2022 and based in Munich. Vanagon invests in outstanding founders who want to radically transform Europe's largest economic sectors. The fund was founded by Axel Roitzsch (serial entrepreneur), Sandro Stark (former Microsoft strategist) and Susanne Fromm (formerly of Allianz Digital & Roland Berger). As experienced early-stage investors, they focus on deep-tech start-ups in the categories of nature, finance and industry that not only have high return potential but also a positive impact on the environment and society.

Vanagon Ventures was advised by Counsel Andrea Schlote (Corporate, Munich).

News & Deals

More News & Deals
Deal Bird & Bird advises Theon on the acquisition of Kappa Optronics

Aug 12 2025

Read More
Deal Bird & Bird advises shareholders of The Payments Association on partnership with Nineteen Group

Aug 07 2025

Read More
News Bird & Bird boosts Dispute Resolution team in Singapore

Aug 06 2025

Read More
Deal Bird & Bird acts for Cornerstone Investors in US$140m placing by Rockhopper Exploration

Aug 06 2025

Read More
Deal Bird & Bird advises ACTUM Digital on Strategic Acquisition of Kuehlhaus AG

Aug 05 2025

Read More
News Bird & Bird Advises Ratiopharm in Landmark Xarelto Patent Revocation Case

Aug 01 2025

Read More